Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | ACACB | O00763 | 4/20 | 0.37 |
| ▸ | NAMPT | P43490 | 7/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.34 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.34 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.34 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539921 | 0.90 | ESR1 (0.38) | CNR1ACACBESR1KCNH2GAA | |
| SCHEMBL6541205 | 0.89 | ABCB11 (0.38) | CNR1ACACBNAMPTESR1KCNH2 | |
| SCHEMBL6800035 | 0.89 | ABCB11 (0.38) | CNR1ACACBNAMPTESR1KCNH2 | |
| SCHEMBL6540840 | 0.89 | NAMPT (0.45) | CNR1ACACBNAMPTMEN1KMT2A | |
| SCHEMBL6541794 | 0.87 | PTPN1 (0.44) | CNR1ACACBNAMPT | |
| SCHEMBL6552876 | 0.87 | ESR1 (0.39) | CNR1ACACBNAMPTESR1KCNH2 | |
| SCHEMBL6540030 | 0.86 | ACACB (0.47) | CNR1ACACBESR1KCNH2GAA | |
| SCHEMBL6540634 | 0.86 | ACACB (0.47) | CNR1ACACBESR1KCNH2GAA | |
| SCHEMBL6552874 | 0.85 | ESR1 (0.38) | CNR1ACACBNAMPTESR1KCNH2 | |
| SCHEMBL6799811 | 0.85 | ABCC9 (0.45) | CNR1ACACBNAMPTESR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1389185-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002094770-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | CNR1 45/4885ACACB 3020/4885NAMPT 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.